Foghorn Therapeutics

Company snapshot

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system inter

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 14 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Foghorn Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Foghorn Therapeutics.

1. Jun 5, 2026 Clinical update

   FHD-286 — Phase 1

2. May 23, 2026 Clinical update

   FHD-286 — Phase 2

3. May 23, 2026 Clinical update

   Decitabine — Phase 1

4. May 23, 2026 Clinical update

   FHD-286 — Phase 1

5. May 23, 2026 Clinical update

   FHD-609 — Phase 1

View all clinical trial activity →

• What is Foghorn Therapeutics?

  Foghorn Therapeutics is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker FHTX. Primary therapeutic focus areas include Acute Myeloid Leukemia, Advanced Hematologic Malignancy, Metastatic Uveal Melanoma, Small Cell Lung Cancer, Advanced Synovia

• Is Foghorn Therapeutics publicly traded?

  Yes. Foghorn Therapeutics is listed with ticker FHTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Foghorn Therapeutics develop or market?

  We link 2 drug profile(s) where Foghorn Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/foghorn-therapeutics#company-drugs.

• What are the latest developments for Foghorn Therapeutics?

  In the last 12 months our linked public records show 5 trial program update(s) and 5 US patent grant(s) tied to this profile.

• What therapeutic areas does Foghorn Therapeutics focus on?

  Foghorn Therapeutics focuses on Acute Myeloid Leukemia, Advanced Hematologic Malignancy, Metastatic Uveal Melanoma based on our analysis of their pipeline programs and drug development activities.